Rein Therapeutics (NASDAQ:RNTX) Major Shareholder Voss Capital, Lp Buys 104,183 Shares of Stock

Rein Therapeutics Inc. (NASDAQ:RNTX) major shareholder Voss Capital, Lp bought 104,183 shares of the company’s stock in a transaction that occurred on Friday, November 14th. The stock was purchased at an average price of $1.22 per share, for a total transaction of $127,103.26. Following the transaction, the insider owned 926,441 shares of the company’s stock, valued at $1,130,258.02. The trade was a 12.67% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. Major shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.

Voss Capital, Lp also recently made the following trade(s):

• On Tuesday, October 28th, Voss Capital, Lp acquired 178,392 shares of Rein Therapeutics stock. The shares were acquired at an average price of $1.39 per share, with a total value of $247,964.88.
• On Monday, October 27th, Voss Capital, Lp acquired 97,482 shares of Rein Therapeutics stock. The stock was acquired at an average cost of $1.37 per share, for a total transaction of $133,550.34.
• On Friday, October 24th, Voss Capital, Lp bought 30,176 shares of Rein Therapeutics stock. The shares were acquired at an average cost of $1.39 per share, with a total value of $41,944.64.

Rein Therapeutics Price Performance

NASDAQ RNTX opened at $1.22 on Wednesday. Rein Therapeutics Inc. has a 1 year low of $1.04 and a 1 year high of $3.50. The company has a market capitalization of $28.43 million, a PE ratio of -0.46 and a beta of 1.15. The company has a fifty day moving average of $1.31 and a 200 day moving average of $1.47.

Rein Therapeutics (NASDAQ:RNTX) last released its quarterly earnings data on Friday, November 14th. The company reported ($0.21) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.03. Research analysts expect that Rein Therapeutics Inc. will post -1.56 earnings per share for the current year.

Analysts Set New Price Targets

A number of research analysts have issued reports on the company. Loop Capital set a $6.00 price target on Rein Therapeutics in a report on Monday, November 3rd. Brookline Capital Management raised shares of Rein Therapeutics from a “hold” rating to a “buy” rating in a report on Monday, November 3rd. HC Wainwright began coverage on shares of Rein Therapeutics in a research report on Monday, September 22nd. They set a “buy” rating and a $10.00 price target on the stock. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Rein Therapeutics in a research report on Wednesday, October 8th. Two research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Rein Therapeutics presently has an average rating of “Hold” and an average target price of $8.00.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the stock. BIOS Capital Management LP purchased a new stake in Rein Therapeutics during the 2nd quarter worth approximately $2,367,000. Voss Capital LP acquired a new stake in shares of Rein Therapeutics in the second quarter worth approximately $2,007,000. University of Texas Texas AM Investment Management Co. purchased a new stake in shares of Rein Therapeutics during the second quarter worth approximately $716,000. Cable Car Capital LP purchased a new stake in shares of Rein Therapeutics during the second quarter worth approximately $588,000. Finally, Vanguard Group Inc. raised its stake in Rein Therapeutics by 32.2% in the 3rd quarter. Vanguard Group Inc. now owns 1,168,407 shares of the company’s stock valued at $1,338,000 after purchasing an additional 284,300 shares during the last quarter. Institutional investors and hedge funds own 90.89% of the company’s stock.

About Rein Therapeutics

Rein Therapeutics, Inc is a clinical stage biopharmaceutical company, which engages in the development and commercialization of a novel class of therapeutics for the treatment of cancer and other diseases. It focuses on its lead product candidate, ALRN-6924, which is a cell-permeating peptide that disrupts the interaction of p53 suppressors MDM2 and MDMX with tumor suppressor p53 to reactivate tumor suppression in non-mutant, or wild-type, p53 cancers.